Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib in Advanced Melanoma
NCT00436605Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Dec 2006
- Primary completion
- Mar 2010
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib in melanoma, sponsored by National Cancer Institute. Started Dec 2006; status: completed.
02
Drugs
dasatinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00436605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00436605.